We report the synthesis and characterization of five novel Mo-containing polyoxometalate (POM) bisphosphonate complexes with nuclearities ranging from 4 to 12 and with fully reduced, fully oxidized, or mixed-valent (Mo(V), Mo(VI)) molybdenum, in which the bisphosphonates bind to the POM cluster through their two phosphonate groups and a deprotonated 1-OH group. The compounds were synthesized in water by treating [Mo(V)(2)O(4)(H(2)O)(6)](2+) or [Mo(VI)O(4)](2-) with H(2)O(3)PC(C(3)H(6)NH(2))OPO(3)H(2) (alendronic acid) or its aminophenol derivative, and were characterized by single-crystal X-ray diffraction and (31)P NMR spectroscopy. (NH(4))(6)[(Mo(V)(2)O(4))(Mo(VI)(2)O(6))(2)(O(3)PC(C(3)H(6)NH(3))OPO(3))(2)]·12H(2)O (1) is an insoluble mixed-valent species. [(C(2)H(5))(2)NH(2)](4)[Mo(V)(4)O(8)(O(3)PC(C(3)H(6)NH(3))OPO(3))(2)]·6H(2)O (2) and [(C(2)H(5))(2)NH(2)](6)[Mo(V)(4)O(8)(O(3)PC(C(10)H(14)NO)OPO(3))(2)]·18H(2)O (4) contain similar tetranuclear reduced frameworks. Li(8)[(Mo(V)(2)O(4)(H(2)O))(4)(O(3)PC(C(3)H(6)NH(3))OPO(3))(4)]·45H(2)O (3) and Na(2)Rb(6)[(Mo(VI)(3)O(8))(4)(O(3)PC(C(3)H(6)NH(3))OPO(3))(4)]·26H(2)O (5) are alkali metal salts of fully reduced octanuclear and fully oxidized dodecanuclear POMs, respectively. The activities of 2-5 (which are water-soluble) against three human tumor cell lines were investigated in vitro. Although 2-4 have weak but measurable activity, 5 has IC(50) values of about 10 μM, which is about four times the activity of the parent alendronate molecule on a per-alendronate basis, which opens up the possibility of developing novel drug leads based on Mo bisphosphonate clusters.
No takes yet. Share an insight, caveat, or question.
Compain et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: